An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 70 (1) , 54-59
Abstract
Aims To compare the British Isles Lupus Assessment Group (BILAG) 2004, the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) flare index (SFI) and physician's global assessment (PGA) in assessing flares of disease activity in patients with systemic lupus erythematosus (SLE). Methods Sixteen patients with active SLE were assessed by a panel of 16 rheumatologists. The order in which the patients were seen was randomised using a 4×4 Latin square design. Each patient's flare status was determined at each assessment using the BILAG 2004 activity index; the SFI and a PGA. A group of five specialists designated each patient into severe, moderate, mild or no flare categories. Results The rate of complete agreement (95% CI) of the four individual examining physicians for any flare versus no flare was 81% (55% to 94%), 75% (49% to 90%) and 75% (49% to 90%) for the BILAG 2004 index, SELENA flare instrument and PGA, respectively. The overall agreement between flare defined by BILAG 2004 and the SFI was 81% and when type of flare was considered was 52%. Intraclass correlation coefficients (95% CI), as a measure of internal reliability, were 0.54 (0.32 to 0.78) for BILAG 2004 flare compared with 0.21 (0.08 to 0.48) for SELENA flare and 0.18 (0.06 to 0.45) for PGA. Severe flare was associated with good agreement between the indices but mild/moderate flare was much less consistent. Conclusions The assessment of flare in patients with SLE is challenging. No flare and severe flare are identifiable but further work is needed to optimise the accurate ‘capture’ of mild and moderate flares.Keywords
This publication has 15 references indexed in Scilit:
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- B-cell-depletion therapy in SLE—what are the current prospects for its acceptance?Nature Reviews Rheumatology, 2009
- The BILAG-2004 index is sensitive to change for assessment of SLE disease activityRheumatology, 2009
- New therapies in systemic lupus erythematosus – trials, troubles and tribulations…. working towards a solutionLupus, 2008
- British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosusArthritis & Rheumatism, 2007
- BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosusRheumatology, 2005
- Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective studyRheumatology, 2004
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982